Elizabeth Holmes’ long-shot defense may be all she’s got, experts say:

Font size Theranos founder and former CEO Elizabeth Holmes. Getty Images In testimony at her trial this week, ex-Theranos CEO Elizabeth Holmes said she was the unwitting figurehead of a company controlled by an allegedly abusive ex-boyfriend. It boils down to a brief defense that may be her best hope against allegations she deliberately misled … Read more

Moderna’s patent issues highlight uncertainty for a vaccine star

Font size A federal appeals court issued two rulings unfavorable to Moderna. Sean Gallup/Getty Images The Covid-19 vaccine maker Modern went from being a company largely known by biotech specialists to arguably one of the best-known pharmaceutical brands in the world in less than a year in 2020. But even as the company is expected … Read more

Nuvectis Pharma postpones listing as IPO market becomes cautious

Font size Dream time The high-flying IPO market is still on hiatus as the week’s only offering has been postponed. Nuvectis Pharma was due to open for trading on Wednesday but chose to postpone its IPO, said a person familiar with the situation. Nuvectis did not immediately return messages for comment. Nuvectis, which develops drugs … Read more

Nuvectis Pharma postpones listing as IPO market becomes cautious

Font size Dream time The high-flying IPO market is still on hiatus as the week’s only offering has been postponed. Nuvectis Pharma was due to open for trading on Wednesday but chose to postpone its IPO, said a person familiar with the situation. Nuvectis did not immediately return messages for comment. Nuvectis, which develops drugs … Read more

Merck Covid Pill Gets Limited Approval From FDA Advisors. What’s next.

Font size Merck’s Covid-19 antiviral molnupiravir. Thanks to Merck Expert advisors to the Food and Drug Administration voted 13-10 in favor of the statement that the benefits of: Merck The Covid-19 antiviral molnupiravir outweighed the risks, effectively authorizing the emergency pill. The FDA itself has yet to follow through on the recommendation and will likely … Read more

Merck Covid Pill Gets Limited Approval From FDA Advisors. What’s next.

Font size Molnupiravir from Merck. Thanks to Merck Expert advisors to the Food and Drug Administration voted 13-10 in favor of the statement that the benefits of: Merck The Covid-19 antiviral molnupiravir outweighed the risks, effectively authorizing the emergency pill. The FDA itself has yet to follow through on the recommendation and will likely set … Read more

Merck’s Covid Pill Gets an FDA Hearing. What’s at stake for the shares.

Merck makes clear on Tuesday that it still has a role to play in the Covid-19 treatment landscape. The FDA is convening an advisory committee to consider the company’s antiviral pill, molnupiravir. But the discussion will highlight the drug’s limitations, including safety risks and limited efficacy, which could lower expectations for the drug’s long-term sales … Read more

Omicron variant could boost global growth, according to Goldman Sachs scenario

Font size A bottle of the current Moderna Covid-19 vaccine. The company is investigating what level of protection it offers against the variant of the Omicron coronavirus. Angela Weiss/AFP/Getty Images Global growth could turn out higher than forecast, according to a scenario mapped out by economists on Goldman Sachs , who have attempted to model … Read more

Krystal Biotech Stock Soars 120% After First Gene Therapy For Skin That Heals Injured Children

Font size Initial data from a trial of Krystal Biotech’s drug Vyjuvek was welcomed by investors Monday. Dream time The first gene therapy to be applied to the skin was able to heal the blisters of children with structural skin deficiency. In addition to being the first local gene therapy, the treatment of Crystal Biotech … Read more

Merck shares fall ahead of FDA panel hearing on covid pill

The FDA is convening an advisory committee Tuesday to consider the company’s antiviral pill, molnupiravir. But the discussion will highlight the drug’s limitations, including safety risks and limited efficacy, which could lower expectations for the drug’s long-term sales even more. Analysts generally expect the agency to authorize molnupiravir, although authorization will likely be limited. Shares … Read more